Shares of QuidelOrtho Co. (NASDAQ:QDEL – Get Free Report) have received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $96.75.
Several research firms have recently commented on QDEL. Raymond James decreased their target price on QuidelOrtho from $110.00 to $100.00 and set a “strong-buy” rating on the stock in a research report on Thursday, November 2nd. Citigroup restated a “neutral” rating and set a $72.00 target price (down from $95.00) on shares of QuidelOrtho in a research note on Monday, December 11th. Royal Bank of Canada decreased their price objective on QuidelOrtho from $140.00 to $130.00 and set an “outperform” rating for the company in a report on Thursday, December 21st. Finally, William Blair reiterated an “outperform” rating on shares of QuidelOrtho in a report on Thursday, November 2nd.
QuidelOrtho Stock Performance
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Money Concepts Capital Corp grew its stake in QuidelOrtho by 66.8% in the 4th quarter. Money Concepts Capital Corp now owns 337 shares of the company’s stock valued at $29,000 after buying an additional 135 shares in the last quarter. Global Retirement Partners LLC grew its stake in QuidelOrtho by 109.0% in the 3rd quarter. Global Retirement Partners LLC now owns 347 shares of the company’s stock valued at $26,000 after buying an additional 181 shares in the last quarter. Eagle Bay Advisors LLC grew its stake in QuidelOrtho by 174.2% in the 2nd quarter. Eagle Bay Advisors LLC now owns 351 shares of the company’s stock valued at $34,000 after buying an additional 223 shares in the last quarter. First Horizon Advisors Inc. grew its position in shares of QuidelOrtho by 48.6% during the 1st quarter. First Horizon Advisors Inc. now owns 822 shares of the company’s stock valued at $73,000 after purchasing an additional 269 shares in the last quarter. Finally, Covestor Ltd grew its position in shares of QuidelOrtho by 104.6% during the 1st quarter. Covestor Ltd now owns 1,207 shares of the company’s stock valued at $136,000 after purchasing an additional 617 shares in the last quarter. 93.87% of the stock is currently owned by hedge funds and other institutional investors.
QuidelOrtho Company Profile
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Five stocks we like better than QuidelOrtho
- Consumer Discretionary Stocks Explained
- 3 attractive stocks that insiders are buying
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What is a buyback in stocks? A comprehensive guide for investors
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.